| Literature DB >> 24485894 |
Luke A Downey1, Jennifer M Loftis2.
Abstract
Central nervous system (CNS) damage associated with psychostimulant dependence may be an ongoing, degenerative process with adverse effects on neuropsychiatric function. However, the molecular mechanisms regarding how altered energy regulation affects immune response in the context of substance use disorders are not fully understood. This review summarizes the current evidence regarding the effects of psychostimulant [particularly 3,4-methylenedioxy-N-methylamphetamine (MDMA) and methamphetamine] exposure on brain energy regulation, immune response, and neuropsychiatric function. Importantly, the neuropsychiatric impairments (e.g., cognitive deficits, depression, and anxiety) that persist following abstinence are associated with poorer treatment outcomes - increased relapse rates, lower treatment retention rates, and reduced daily functioning. Qualifying the molecular changes within the CNS according to the exposure and use patterns of specifically abused substances should inform the development of new therapeutic approaches for addiction treatment. Published by Elsevier B.V.Entities:
Keywords: 2-Fluoro-2-deoxy-d-glucose (PubChem CID: 315411); 3,4-Methylenedioxy-N-methylamphetamine (MDMA); 3,4-Methylenedioxy-N-methylamphetamine (MDMA) (PubChem CID: 1615); 3,4-Methylenedioxyethamphetamine (MDE) (PubChem CID: 105039); Bioenergetics; Cocaine (PubChem CID: 5760); Inflammation; Methamphetamine; Methamphetamine (PubChem CID: 10836); Neurodegenerative diseases; Oxidative stress
Mesh:
Substances:
Year: 2014 PMID: 24485894 PMCID: PMC3970781 DOI: 10.1016/j.ejphar.2014.01.032
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432